SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-23-066787
Filing Date
2023-11-29
Accepted
2023-11-29 16:45:46
Documents
2
Period of Report
2023-11-27

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1608
2 EX-24.1 amlx-ex24_1.htm EX-24.1 8776
  Complete submission text file 0000950170-23-066787.txt   11729
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Bedrosian Camille L (Reporting) CIK: 0001326969 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41199 | Film No.: 231452958

Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Issuer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations